CN105712937B - A kind of compound and application thereof for treating metastatic tumo(u)r - Google Patents
A kind of compound and application thereof for treating metastatic tumo(u)r Download PDFInfo
- Publication number
- CN105712937B CN105712937B CN201610106954.XA CN201610106954A CN105712937B CN 105712937 B CN105712937 B CN 105712937B CN 201610106954 A CN201610106954 A CN 201610106954A CN 105712937 B CN105712937 B CN 105712937B
- Authority
- CN
- China
- Prior art keywords
- compound
- added
- silica gel
- deuterated
- column
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
Abstract
The invention discloses a kind of compound and application thereof for treating metastatic tumo(u)r, compounds shown in formula I, wherein R1-R8 is respectively and independently selected from the alkyl or part deuteroalkyl of H, D, C1-C3.The compound is a kind of new drug for treating metastatic tumo(u)r developed on the basis of veliparib structure, and the activity of PARP can be effectively suppressed.The compound can be used as the drug for the treatment of uterine cancer, lung cancer, gastric cancer, melanoma, breast cancer, prostate cancer, colon cancer or intracranial tumors.
Description
Technical field
The present invention relates to a kind of compounds and application thereof for treating metastatic tumo(u)r.
Background technique
Polyadenylic acid diphosphonic acid phosphoribosynltransferase (PARP) is the novel target spot for the treatment of cancer in recent years.PARP inhibitor is logical
It crosses inhibition DNA of tumor cell injury repair, promote tumour cell that apoptosis occurs, so as to enhance radiotherapy and alkylating agent and platinum class
The curative effect of chemotherapy.Attack is unfolded in " deadly defect " of this drug utilization hereditary breast cancer.This weakness is by being referred to as
Caused by gene defect for " BRCA1 ", the ability that cancer cell repairs damaged dna is limited.Curative effect in addition to chemotherapeutic can be improved
Outside, the patient that PARP inhibitor is mutated BRCA as single medicine is also effective.Patient gene's recombination function of BRCA mutation is scarce
It loses, then inhibits the reparation of DNA by PARP inhibitor, then can kill tumour cell, concept clinical research by double action
In have proven to this theoretical hypothesis.PARP inhibitor not only can produce synergistic effect with BRCA1 or BRCA2 mutation, it is also possible to
There is also Synergistic killing effects for many also not found gene mutations.
Veliparib is the benzimidazoles compound of novel high selection inhibition PARP a kind of, and inside and outside experiment shows this
Product have the significant inhibition active effect of PARP.It is swollen in treatment metastatic breast cancer, colon cancer, metastasis melanin tumor and brain
Significant effect is obtained in terms of tumor, it is clinical to enter the III phase with the research that Temozolomide is combined treatment breast cancer.Perhaps
Mostly novel veliparib is studied, and (for example, Xu Xiuchun, Shi Yu etc., novel PARP inhibitor veliparib is modern with application
Drug and clinical, 2013,28 (1): 69-73.
But for the research of veliparib class drug also in the exploratory stage, therefore in the structure base of veliparib
A kind of new drug that can effectively treat tumour is researched and developed on plinth, it is particularly important.
Summary of the invention
The object of the present invention is to provide a kind of compounds and application thereof for treating metastatic tumo(u)r.
The present invention provides Formulas I compound represented:
Formulas I
Wherein, R1-R8 is respectively and independently selected from the alkyl or part deuteroalkyl of H, D, C1-C3.
Further, the R1-R8 is respectively and independently selected from the alkyl or part deuteroalkyl of H, D, C1-C3.
Further, at least one in the R1-R8 is deuterium.
The present invention also provides purposes of the compound shown in Formulas I in preparation treatment metastatic tumo(u)r drug.
Further, the drug is PARP inhibitor class drug.
Further, the drug is the drug for treating uterine cancer, lung cancer, gastric cancer, melanoma or breast cancer.
Further, the drug is the drug for treating prostate cancer, colon cancer or intracranial tumors.
Specific embodiment
Below by specific embodiment, the present invention is further elaborated, but the present invention is not limited thereto.
Experimental method described in following embodiments is unless otherwise specified conventional method；The reagent and material, such as
Without specified otherwise, commercially obtain.
The compound that the present invention treats metastatic tumo(u)r is selected from following any compound:
C1:
C2:
C3:
C4:
The synthesis of embodiment 1:2,3- diaminobenzene formamide
Into 500mL there-necked flask be added N,N-dimethylformamide (DMF) 80ml, 2,3- diaminobenzoic acid (9.1g,
60mmol), it stirs, thionyl chloride 10g is added dropwise in constant pressure funnel, and 30 DEG C are heated to after being added dropwise overnight, is then heated to
50 DEG C, ammonia aqueous solution 75g is added dropwise, reacts 3h, water 100ml is added, stirs 2h, is cooled to room temperature overnight, filtering product is used in combination
500ml water washing 5 times, 50ml isopropanol wash 1 time, room temperature in vacuo it is dry crude product 5.6g.Mass spectrum: 152.2(M+H+).
The synthesis of the deuterated benzamide of embodiment 2:2,3- diamino -5,6- two
Heavy water 20mL is added into 50ml Schlenk pipe, 2,3- diaminobenzene formamide 2g, saleratus 3g are added
Palladium carbon 50mg, hydrogen substitution gas is three times.100 DEG C of heating water bath 72h, the reversed column column chromatographic purifying of alkalinity obtain target product
1.3g, yield 65%.Mass spectrum: 154.2(M+H+).
Embodiment 3: the synthesis of compound C1
The deuterated benzamide (1.6g, 10mmol) of 2,3- diamino -5,6- two is added into the there-necked flask of 100ml, adds 2-
Methylimidazole (0.95g, 11mmol), sulphur powder (3.2g, 100mmol) stir 6h at 170 DEG C, methylene chloride are added after cooling
60ml dissolution, silica gel mixed sample concentration, silica gel chromatographic column, column chromatography for separation obtain target product 0.21g, yield 9%.Mass spectrum:
234.1(M+H+).1H NMR (CD3OD, 400 MHz, TMS): 7.82 (s,1H, Ph-H), 5.43 (s, 1H, Ph-
H), 2.60 (m, 2H,-CH2-), 2.52 (m, 2H,-CH2-)。:
Embodiment 4: the synthesis of compound C2
The deuterated benzamide (1.6g, 10mmol) of 2,3- diamino -5,6- two is added into the there-necked flask of 100ml, adds 2-
Two deuterated imidazoles (0.95g, 11mmol) of methyl -4,4-, sulphur powder (3.2g, 100mmol) stir 6h at 170 DEG C, are added after cooling
Methylene chloride 60ml dissolution, silica gel mixed sample concentration, silica gel chromatographic column, column chromatography for separation obtain target product 0.18g, yield
7.6%.Mass spectrum: 236.2(M+H+).1H NMR (CD3OD, 400 MHz, TMS): 7.82 (s,1H, Ph-H) , 5.52
(s, 1H, Ph-H), 2.58 (m, 2H,-CH2-)。
Embodiment 5: the synthesis of compound C3
The deuterated benzamide (1.6g, 10mmol) of 2,3- diamino -5,6- two is added into the there-necked flask of 100ml, is added
The deuterated imidazoles (0.95g, 11mmol) of 2- methyl -4,4,5,5- four, sulphur powder (3.2g, 100mmol) stir 6h at 170 DEG C, cooling
Methylene chloride 60ml dissolution, silica gel mixed sample concentration are added afterwards, silica gel chromatographic column, column chromatography for separation obtains target product 0.12g, receives
Rate 5%.Mass spectrum: 238.2(M+H+).1H NMR (CD3OD, 400 MHz, TMS): 7.82 (s,1H, Ph-H), 5.45
(s, 1H, Ph-H)。
Embodiment 6: the synthesis of compound C4
2,3- diaminobenzene formyl (3.2g, 20mmol) is added into the there-necked flask of 100ml, methyl -4,4,5 2- are added,
Tetra- deuterated imidazoles (0.95g, 11mmol) of 5-, sulphur powder (3.2g, 100mmol) stir 6h at 170 DEG C, dichloromethane are added after cooling
Alkane 60ml dissolution, silica gel mixed sample concentration, silica gel chromatographic column, column chromatography for separation obtain target product 0.12g, yield 5%.Mass spectrum:
236.2(M+H+).1H NMR (CD3OD, 400 MHz, TMS): 7.95 (d, J = 8.8 Hz, 1H, Ph-H), 7.82
(t, J = 8.4 Hz , 1H, Ph-H), 7.63 (d, J = 8.8 Hz, 1H, =CH-), 5.72 (s, 1H, Ph-
H)。
Purposes and its beneficial of the compound of the present invention in treatment metastatic tumo(u)r is illustrated below by way of experimental example
Effect.
Experimental example a: the pharmacokinetics of the compounds of this invention
Rabbit 10, weight 1kg-1.5kg.Test preceding fasting for 24 hours, free water.Each testedization of stomach-filling 5mg/mg respectively
Close object, compound with 5%DMSO, 5% Tween-80,90% 0.5%CMC-Na prepare, administered volume 10mL/kg.After administration
3h is unified to feed.After administration 0.25,0.5,1.0,2.0,4.0,6.0,12, and for 24 hours, each time point randomly selects 3 rabbits
Son is placed in EDTA test tube at the time point set above in auricular vein extracting vein blood 0.5mL, 12000rpm centrifugation
10min, separated plasma are sealed in -20 DEG C of refrigerator-freezers.It goes 100 μ L serum into clean centrifuge tube with liquid-transfering gun, is added
Acetonitrile (CH3CN it) dilutes, and is centrifuged.Extracting centrifugal liquid detects drug concentration with LC-MS, the results are shown in Table 1.
Table 1 the result shows that, the peak concentration of drug of the compounds of this invention is high, drug absorption degree is preferable, eliminates half-life period and is better than
The drug effect of clinical use can be improved in veliparib, reduces dosage rate.
Experimental example b: external activity experiment
It is being 8.0) 1mM DTT and 4 mM MgCl containing 50mM Tris(pH2Enzyme assay is carried out in buffer solution.
PARP is reacted comprising 1.5 μm of [3M]-NAD+ (1.6 μ Ci/mmol), 200nM biotin histone h1,200nM slDNA, and
1nM PARP or 4nM PARP-2 enzyme.SPA detection is carried out on 96 orifice plates added with 100 μ L reaction solutions.Contain PARP in 50uL
With 50 μ L 2 × NAD+ substrate mixtures are added in 2 × enzyme solution mixture of DNA, reaction starts.150 μ L 1.5mM this first are added
Amide reaction stops.170 μ L reaction terminating liquids are transferred on the coated flash plate of Streptavidin, are incubated 1 hour, use is miniature
Plate scintillation counter counts.Ki data by under various concentration test-compound inhibiting rate curve determine.
The external activity of the compounds of this invention
It is concluded that the compound of the present invention has good rejection ability, wherein compound to PARP enzyme from table
C2 is better than control drug Veliparib.
Comprehensive Experiment statistics indicate that, compound peak concentration of drug prepared by the present invention is high, drug absorption degree is preferable, can be used as
PARP inhibitor has anti-tumor activity, especially has to metastatic gastric carcinoma, lung cancer, column gland cancer, colon cancer or intracranial tumors etc. good
Good therapeutic activity, provides new selection for clinical application.
Claims (1)
1. a kind of synthetic method for the compound for treating metastatic tumo(u)r, the compound in C2, C3, C4 compound one
Kind, it is characterised in that: the synthetic method step of C2, C3, C4 compound are as follows: 1) 2,3- diamino -5,6-, bis- deuterated benzene
The synthesis of formamide
Heavy water 20mL is added into 50ml Schlenk pipe, 2,3- diaminobenzene formamide 2g, saleratus 3g add palladium carbon
50mg, three times, 100 DEG C of heating water bath 72h, the reversed column column chromatographic purifying of alkalinity obtains target product 1.3g to hydrogen substitution gas, receives
Rate 65%, mass spectrum: 154.2(M+H+)；2) synthesis of compound C2
2,3- diamino -5,6- bis- deuterated benzamide 1.6g, 10mmol are added into the there-necked flask of 100ml, adds methyl -4 2-,
4- bis- deuterated imidazoles 0.95g, 11mmol stirs 6h at 3.2g, 100mmol, 170 DEG C of sulphur powder, methylene chloride is added after cooling
60ml dissolution, silica gel mixed sample concentration, silica gel chromatographic column, column chromatography for separation obtain target product 0.18g, yield 7.6%, mass spectrum:
236.2(M+H+),1H NMR (CD3OD, 400 MHz, TMS): 7.82 (s,1H, Ph-H) , 5.52 (s, 1H, Ph-
H), 2.58 (m, 2H,-CH2-)；On connect 1) step, the synthetic method of compound C3 be,
2,3- diamino -5,6- bis- deuterated benzamide 1.6g, 10mmol are added into the there-necked flask of 100ml, 2- first is added
Base -4,4,5,5- tetra- deuterated imidazoles 0.95g, 11mmol stir 6h at 3.2g, 100mmol, 170 DEG C of sulphur powder, are added after cooling
Methylene chloride 60ml dissolution, silica gel mixed sample concentration, silica gel chromatographic column, column chromatography for separation obtain target product 0.12g, yield 5%,
Mass spectrum: 238.2(M+H+),1H NMR (CD3OD, 400 MHz, TMS): 7.82 (s,1H, Ph-H), 5.45 (s, 1H,
Ph-H)；The synthetic method of compound C4 is,
It is added 2,3- diaminobenzene formamide 3.2g, 20mmol into the there-necked flask of 100ml, is added 2- methyl -4,4,5,5- tetra-
Deuterated imidazoles 0.95g, 11mmol, 6h is stirred at 3.2g, 100mmol, 170 DEG C of sulphur powder, and it is molten that methylene chloride 60ml is added after cooling
Solution, silica gel mixed sample concentration, silica gel chromatographic column, column chromatography for separation obtain target product 0.12g, yield 5%, mass spectrum: 236.2(M+H+),1H NMR (CD3OD, 400 MHz, TMS): 7.95 (d, J = 8.8 Hz, 1H, Ph-H), 7.82 (t, J =
8.4 Hz , 1H, Ph-H), 7.63 (d, J = 8.8 Hz, 1H, =CH-), 5.72 (s, 1H, Ph-H)。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610106954.XA CN105712937B (en) | 2016-02-28 | 2016-02-28 | A kind of compound and application thereof for treating metastatic tumo(u)r |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610106954.XA CN105712937B (en) | 2016-02-28 | 2016-02-28 | A kind of compound and application thereof for treating metastatic tumo(u)r |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105712937A CN105712937A (en) | 2016-06-29 |
| CN105712937B true CN105712937B (en) | 2019-02-22 |
Family
ID=56157073
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610106954.XA Active CN105712937B (en) | 2016-02-28 | 2016-02-28 | A kind of compound and application thereof for treating metastatic tumo(u)r |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105712937B (en) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19920936A1 (en) * | 1999-05-07 | 2000-11-09 | Basf Ag | Heterocyclically substituted benzimidazoles, their preparation and use |
| DE10238002A1 (en) * | 2002-08-20 | 2004-03-04 | Merck Patent Gmbh | benzimidazole derivatives |
| EP2329818A1 (en) * | 2006-01-17 | 2011-06-08 | Abbott Laboratories | Combination therapy with PARP inhibitors |
-
2016
- 2016-02-28 CN CN201610106954.XA patent/CN105712937B/en active Active
Non-Patent Citations (3)
| Title |
|---|
| Efficient H/D Exchange Reactions of Alkyl-Substituted Benzene Derivatives by Means of the Pd/C–H2–D2O System;Hiroyoshi Esaki et al.;《Chem. Eur. J.》;20071231;第13卷;第4052-4063页 |
| New method for synthesis of 2-hetaryl-substituted imidazo[4,5-b]pyridine and imidazo[4,5-c]pyridine;Yutilov, Yu. M.; Kovaleva, L. I.;《Khimiya Geterotsiklicheskikh Soedinenii》;19771231;第4卷;第553-534页 |
| Synthesis and proton NMR spectra of 2-heteroaryl-substituted imidazo[4,5-b]pyridines and imidazo[4,5-c]pyridines;Yutilov, Yu. M.; Shcherbina, L. I.; Efremenko, A. F.;《Khimiya Geterotsiklicheskikh Soedinenii》;19891231(第7期);第940-947页 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105712937A (en) | 2016-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109153626B (en) | Preparation method of 2-hydroxy-4- (2, 3-disubstituted benzyloxy) -5-substituted benzaldehyde derivative | |
| EP3055290B1 (en) | Inhibitors of kras g12c | |
| KR20190097201A (en) | Benzisothiazole, isothiazolo [3,4-B] pyridine, quinazoline, phthalazine, pyrido [2,3-D] pyridazine, as KRAS G12C inhibitors for the treatment of lung cancer, pancreatic cancer or colon cancer Pyrido [2,3-D] pyrimidine derivatives | |
| KR20200010306A (en) | Covalent Inhibitors of KRAS | |
| CN105461695A (en) | Pyrimidine or triazine derivative, and preparation method and use thereof | |
| Mashayekh et al. | An overview of recent advances in the applications of click chemistry in the synthesis of bioconjugates with anticancer activities | |
| JP2018520195A (en) | Substituted quinazoline compounds and their use as inhibitors of G12C mutant KRAS, HRAS and / or NRAS proteins | |
| Toolabi et al. | 6-Cinnamoyl-4-arylaminothienopyrimidines as highly potent cytotoxic agents: Design, synthesis and structure-activity relationship studies | |
| CN104302635A (en) | 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereof | |
| CN106946792B (en) | A kind of hydroxamic acid derivs of phthalazone and the preparation method and application thereof | |
| CN104892510A (en) | Preparation method of isocorydaline | |
| CN103450176B (en) | One class is containing 2-(4-aminophenyl) benzothiazole naphthalimide compound and application thereof | |
| CN105712937B (en) | A kind of compound and application thereof for treating metastatic tumo(u)r | |
| CN103694218A (en) | Pyrimidine compound, PI3K inhibitor, pharmaceutical composition comprising PI3K inhibitor and application of inhibitor and pharmaceutical composition | |
| CN106083850B (en) | A kind of pyrimido naphthalimide derivative and its preparation method and application | |
| CN108084178A (en) | Hydroxamic acid compound of the one kind containing tetrahydrochysene-β-Ka Lin structures, purposes and preparation method thereof | |
| Dong et al. | Design, synthesis and biological evaluation of novel c-Met/HDAC dual inhibitors | |
| Abd El-Karim et al. | Rational design and synthesis of novel quinazolinone N-acetohydrazides as type II multi-kinase inhibitors and potential anticancer agents | |
| Khetmalis et al. | Design, synthesis, and biological evaluation of tetrahydroisoquinoline based hydroxamate derivatives as HDAC 6 inhibitors for cancer therapy | |
| Ma et al. | Identification of benzofused five-membered sultams, potent dual NOD1/NOD2 antagonists in vitro and in vivo | |
| CN102775381B (en) | Substituted hydrazide compound, and its preparation method, medicinal compositions and application | |
| CN105601631A (en) | 2,4-disubstituted-5-chloropyrimidine derivative, preparation method and medical applications thereof | |
| CN109824753A (en) | Tanshinone IIA derivative with IDO/TDO double selectivity inhibitory activity | |
| CN107353287B (en) | A kind of quinoxaline and heterocyclic fourth ketone compounds and its application in antitumor | |
| CN108947904B (en) | Compound containing seven-membered lactam ring and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20190110 Address after: 050000 Room 405, Fourth Floor, International Talent City, International 9 Building, Runjiang Headquarters, 319 Changjiang Avenue, Shijiazhuang High-tech Zone, Hebei Province Applicant after: Hebei Ningge Biomedical Technology Co., Ltd. Address before: 250000 117 Lishan Road, Lixia District, Ji'nan, Shandong 2-301 Applicant before: Li Jian |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |